Table of Contents:

Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Diagnosis
6.1
6.2 Fluroscein Angiography (FA)
6.2.1 Market Estimates & Forecast, 2017 - 2023
6.3 Fundus Autofluorescence (FAF)
6.3.1 Market Estimates & Forecast, 2017 - 2023
6.4 Optical Coherence Tomography (OCT)
6.4.1 Market Estimates & Forecast, 2017 - 2023
6.5 Electroretinography
6.5.1 Market Estimates & Forecast, 2017 - 2023
Chapter 7. Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Devices
7.1
7.2 Magnifying Spectacles
7.2.1 Market Estimates & Forecast, 2017 - 2023
7.3 Magnifiers
7.3.1 Market Estimates & Forecast, 2017 - 2023
7.4 Reading telescopes
7.4.1 Market Estimates & Forecast, 2017 - 2023
Chapter 8 Global Juvenile Macular Degeneration (Stargardt Disease) Market, by End Users
8.1 Introduction
8.2 Hospitals & Eye Clinics
8.2.1 Market Estimates & Forecast, 2017 - 2023
8.3 Research & Academic Institutes
8.3.1 Market Estimates & Forecast, 2017 - 2023
Chapter 9. Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa
Chapter 10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 11 Company Profiles
11.1 Alkeus Pharmaceuticals Inc.
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Astellas Pharma Inc
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Allergan PLC
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Pfizer
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 PfBausch + Lomb
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Gilead Sciences Inc.
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 Gilead Sciences Inc.
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financial
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Others
Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO's View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Medical End Users Industry
Chapter 13 Appendix